Genelux Corporation
NASDAQ: GNLX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Thomas D. Zindrick
- Employees
- 24
- Headquarters
- Westlake Village, United States
- IPO year
- 2023
- Market cap
- $107.2M
- Website
- https://www.genelux.com
Loading GNLX…
Loading profile data…Frequently asked questions about GNLX
What does Genelux Corporation (GNLX) do?
Genelux Corporation is a clinical-stage biopharmaceutical company focused on pioneering advanced oncolytic viral immunotherapies for patients confronting aggressive and/or hard-to-treat solid tumor malignancies. Its leading experimental drug, Olvi-Vec, is a proprietary, engineered vaccinia virus strain being developed to address ovarian cancer a...
Where does GNLX trade?
Genelux Corporation (GNLX) trades on the NASDAQ Global Market.
What sector is GNLX in?
Genelux Corporation (GNLX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Genelux Corporation?
Thomas D. Zindrick is the chief executive officer of Genelux Corporation (GNLX).
Where is Genelux Corporation headquartered?
Genelux Corporation is headquartered in United States.
Does GNLX pay a dividend?
Genelux Corporation (GNLX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did GNLX go public?
Genelux Corporation (GNLX) completed its initial public offering in 2023.